1. Home
  2. HCC vs TGTX Comparison

HCC vs TGTX Comparison

Compare HCC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Warrior Met Coal Inc.

HCC

Warrior Met Coal Inc.

HOLD

Current Price

$101.00

Market Cap

4.6B

Sector

Energy

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.74

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCC
TGTX
Founded
2015
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Coal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
5.5B
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
HCC
TGTX
Price
$101.00
$30.74
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$76.40
$51.60
AVG Volume (30 Days)
750.1K
2.4M
Earning Date
02-12-2026
03-02-2026
Dividend Yield
0.32%
N/A
EPS Growth
N/A
N/A
EPS
0.67
2.78
Revenue
$1,224,320,000.00
$531,898,000.00
Revenue This Year
N/A
$87.88
Revenue Next Year
$47.01
$47.78
P/E Ratio
$149.58
$11.01
Revenue Growth
N/A
100.88
52 Week Low
$38.00
$25.28
52 Week High
$105.35
$46.48

Technical Indicators

Market Signals
Indicator
HCC
TGTX
Relative Strength Index (RSI) 79.63 53.06
Support Level $86.85 $26.89
Resistance Level $105.35 $33.24
Average True Range (ATR) 3.36 1.56
MACD 0.77 0.14
Stochastic Oscillator 77.05 60.55

Price Performance

Historical Comparison
HCC
TGTX

About HCC Warrior Met Coal Inc.

Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: